A detailed history of Ausdal Financial Partners, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Ausdal Financial Partners, Inc. holds 3,397 shares of LLY stock, worth $2.7 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
3,397
Previous 3,142 8.12%
Holding current value
$2.7 Million
Previous $2.84 Million 5.8%
% of portfolio
0.34%
Previous 0.32%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

BUY
$772.14 - $960.02 $196,895 - $244,805
255 Added 8.12%
3,397 $3.01 Million
Q2 2024

Aug 06, 2024

SELL
$724.87 - $909.04 $97,857 - $122,720
-135 Reduced 4.12%
3,142 $2.84 Million
Q1 2024

Apr 12, 2024

BUY
$592.2 - $792.28 $17,173 - $22,976
29 Added 0.89%
3,277 $2.55 Million
Q4 2023

Jan 11, 2024

BUY
$525.19 - $619.13 $92,433 - $108,966
176 Added 5.73%
3,248 $1.89 Million
Q3 2023

Nov 08, 2023

SELL
$434.7 - $599.3 $37,384 - $51,539
-86 Reduced 2.72%
3,072 $1.65 Million
Q2 2023

Jul 31, 2023

BUY
$350.74 - $468.98 $61,379 - $82,071
175 Added 5.87%
3,158 $1.48 Million
Q1 2023

May 04, 2023

SELL
$310.63 - $364.82 $34,169 - $40,130
-110 Reduced 3.56%
2,983 $1.02 Million
Q4 2022

Feb 03, 2023

BUY
$321.55 - $374.67 $218,332 - $254,400
679 Added 28.13%
3,093 $1.13 Million
Q3 2022

Nov 09, 2022

BUY
$296.48 - $337.87 $28,758 - $32,773
97 Added 4.19%
2,414 $781,000
Q1 2022

May 04, 2022

BUY
$234.69 - $291.66 $70,641 - $87,789
301 Added 14.93%
2,317 $663,000
Q4 2021

Feb 08, 2022

SELL
$224.85 - $279.04 $20,236 - $25,113
-90 Reduced 4.27%
2,016 $557,000
Q3 2021

Nov 01, 2021

SELL
$221.6 - $272.71 $30,137 - $37,088
-136 Reduced 6.07%
2,106 $487,000
Q2 2021

Jul 19, 2021

SELL
$180.55 - $233.54 $48,567 - $62,822
-269 Reduced 10.71%
2,242 $515,000
Q1 2021

May 05, 2021

BUY
$164.32 - $212.72 $39,601 - $51,265
241 Added 10.62%
2,511 $469,000
Q4 2020

Feb 01, 2021

BUY
$130.46 - $172.63 $25,178 - $33,317
193 Added 9.29%
2,270 $383,000
Q3 2020

Nov 04, 2020

BUY
$146.22 - $169.13 $30,267 - $35,009
207 Added 11.07%
2,077 $307,000
Q1 2020

May 04, 2020

SELL
$119.05 - $147.35 $44,643 - $55,256
-375 Reduced 16.7%
1,870 $295,000
Q4 2019

Feb 14, 2020

SELL
$106.92 - $132.43 $34,107 - $42,245
-319 Reduced 12.44%
2,245 $314,000
Q2 2019

Aug 05, 2019

BUY
$110.79 - $129.32 $25,481 - $29,743
230 Added 9.85%
2,564 $279,000
Q1 2019

May 13, 2019

SELL
$111.31 - $131.02 $31,945 - $37,602
-287 Reduced 10.95%
2,334 $303,000
Q4 2018

Feb 11, 2019

SELL
$105.9 - $118.64 $65,234 - $73,082
-616 Reduced 19.03%
2,621 $303,000
Q3 2018

Nov 09, 2018

BUY
$85.86 - $107.31 $5,924 - $7,404
69 Added 2.18%
3,237 $347,000
Q2 2018

Aug 08, 2018

SELL
$75.7 - $86.88 $32,172 - $36,924
-425 Reduced 11.83%
3,168 $270,000
Q1 2018

Apr 20, 2018

BUY
$74.21 - $87.6 $40,370 - $47,654
544 Added 17.84%
3,593 $278,000
Q4 2017

Feb 08, 2018

BUY
$81.94 - $87.89 $81 - $87
1 Added 0.03%
3,049 $258,000
Q3 2017

Oct 31, 2017

BUY
$77.07 - $85.54 $234,909 - $260,725
3,048
3,048 $261,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $755B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Ausdal Financial Partners, Inc. Portfolio

Follow Ausdal Financial Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ausdal Financial Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ausdal Financial Partners, Inc. with notifications on news.